3Alwayn IP, Andersson C, Lee S, et al. Inhibition of matrix metalloproteinases increases PPAR - alpha and IL - 6 and prevents dietary - induced hepatic steatosis and injury in a murine model [J]. Am J Physiol Gastrointest Liver Physiol, 2006, 291:1011-1009.
4Lutehman G, Promrat K, Kleiner DE, et al. Changes in serum adipokine levels during pioglitazone treatment for nonalcoholic steatohepa - titis: relationship to histological improvement [ J ]. Clin Gastroenterol Hepatol, 2006, 4: 1048-1052.
5Joshi - Barve S, Barve SS, Amancherla K, et al. Palmitic acid induces production of proinflammatory cytokine interleukin - 8 from hepatocytes [J]. Hepatology, 2007, 46:823-830.
6Bahcecioglu, Yalniz M, Ataseven H, et al. Levels of serum hyaluronic acid, TNF-alpha and IL- 8 in patients with nonalcoholic steatohepatitis [J]. Hepatosastroenterology, 2005, 52: 1549-1553.
7Abiru S, Migita K, Maeda Y, et al. Serum cytokine and soluble cytokine receptor levels in patients with non - alcoholic steatohepatitis [ J ].Liver lnt, 2006, 26:39 - 45.
8Gonzalez - Quintela A, Dominguez - Santalla M J, Perez LF, et al. Influence of acute alcohol intake and alcohol withdrawal on circulating levelsofIL-6, IL-8, IL-10andIL-12 [J]. Cytokine, 2000, 12: 1437 - 1440.
9Song Z, Joshi - Barve S, Barve S, et al. Advances in alcoholic liver disease [J]. Curr Gastroenterol Rep, 2004, 6 (1): 71 -76.
10Garcia - Ruiz I, Rodriguez - Juan C, Diaz - Sanjuan T, et al. Uric acid and anti-TNF antibody improve mitochondrial dysfunction in ob/ ob mice [J]. Hepatology, 2006, 44:581-591.
二级参考文献22
1Bugianesi E,Zannoni C,Vanni E,et al.Non-alcoholic fatty liver and insulin resistance:a cause-effect relationship? Digestive and Liver Disease,2004,36:333-336
2Kota BP,Huang TH,Roufogalis BD.An overview on biological mechanisms of PPAR.Pharmacological Research,2005,51:85-94
3Metzger D,Imai T,Jiang M,et al.Functional role of RXRs and PPARy in mature adipocytes.Prostaglandins Leukot Essent Fatty Acids,2005,73:51-58
4Giusti V,Verdumo C,Suter M,et al.Expression of Peroxisome proliferator activated receptor gammal and Peroxisome proliferator activated receptor gamma2 in viscerl and subcutaneous adipose tissue of obese women.Diabates,2003,52:1673-1676
6Olefsky JM.Tteatment of insulin resistance with Peroxisome proliferator activated receptor gamma agonists.Clin Invest,2000,106:467-472
7Akiyama TE,Nicol CJ,Gonzalez FJ.on par with PPARs.Trends Gene,2001,17:310-312
8Hammarstedt A,Andersson CX,Rotter Sopasakis V.The effect of PPARy ligands on the adipose tissue in insulin resistance.Leukotrienes and Essential Fatty Acids,2005,73:65-75
9Mori Y,Murakawa Y,Okada K,et al.Effecct of roglitazone on body fat distribution in type 2 diabetic patients.Diabetes Care,1999,22:908-912
10Vidal Puig AJ,Considine RV.Peroxisome proliferator activated receptor expression human tissues:Effects of obesity,weightloss,and regulation by insulin and glucocorticoid.J Clin Invest,1997,99:2416-2422
8Alwayn IP,Andersson C,Lee S,et al.Inhibition of matrix metalloproteinases increases PPAR-alpha and IL-6 and prevents dietary-induced hepatic steatosis and injury in a murine model[J].Am J Physiol Gastrointest Liver Physiol,2006,291:1 009-1 011.
9Luchman G,Promrat K,Kleiner DE,et al.Changes in serum adipokine levels during pioglitazone treatment for nonalcoholic steatopepatitis:relationship to histological improvement[J].Clin Gastroenterol Hepatol,2006,4:1 048-1 052.
10Gonzalez-Quintela A,Dominguez-Santalla MJ,Perez LF,et al.Influence of acute alcohol intake and alcohol withdrawal on circulating levels of IL-6,IL-8,IL-10 and IL-12[J].Cytokine,2000,12:1 437-1 440.
